Introduction
Since its initial description, endogenous suppression of tumorigenesis has been a cornerstone and topic of intensive investigation in cancer research (1) . Today, we appreciate that cells employ a growing assortment of genes to restrict proliferation and prevent tumor growth, including those that function in cell cycle checkpoints and mitogenic signalling (2) (3) (4) .
Identification of changes to the genetic material encoding critical regulators of these processes is a central theme in efforts toward understanding cancer development, as all cancers carry tumorigenic somatic mutations (5, 6) .
Current thought on tumor suppressor loss suggests a more fluid continuum model, in which subtle, but critical, changes in tumor suppressor levels can have drastic effects on the development of cancer, rendering haploinsufficiencies and partial losses just as tumorigenic as "two hits" (7) . Chromosome 17 has emerged as a lightning rod of cancer-associated genetic mutations and rearrangements, with the 17p arm in particular a noted hotspot for deletions (8) (9) (10) . However, the identity of specific genes with tumor suppressive function within these regions has remained elusive. The MKK3 gene is located on chromosome 17p11.2, and recent proteomeprofiling work has highlighted MKK3 as a senescence-promoting and generally downregulated protein in immortalized mammary epithelial cells (11) , adding weight to the pursuit of mechanistic insight into the functional role of MKK3 activity in breast cancer.
Breast cancer is the most commonly diagnosed cancer in women and second-leading cause of cancer-related deaths, statistics which strongly advocate for a better understanding of the mechanisms that underlie mammary carcinogenesis (12) . In this report, we show that MKK3 expression is impaired in malignant mammary tissues and identify a significant copy number loss of genomic MKK3 in human breast cancer patients. 
Materials and Methods

Pathology samples from breast cancer patients
The Ethics Committee of Chinese PLA General Hospital in Beijing approved this study, and informed consent was obtained from the patients. All pathology samples and clinical information were collected in accordance with institutional guidelines and regulations.
Animals
Immunodeficient Rag1 
Antibodies and Reagents
Antibodies to cyclin-dependent kinase inhibitors p21, p27, p16, p15, p18, and p57 as well as phospho-ATF2, phospho-p53 (Ser6; Ser9; Ser15; Thr81; Ser20; Ser33; Ser37; Ser46; Ser392), phospho-Akt, total Akt, and c-Jun were purchased from Cell Signaling Technology, Inc.
(Beverly, MA). Antibodies for MKK3 (C-19), actin, and HRP-linked secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody for phospho-p21 (Ser130) was from Biorbyt (San Francisco, CA). FITC-conjugated antibodies to Flag were from Sigma (Oakville, ON). Alexa 594-conjugated goat anti-rabbit secondary was from Invitrogen (Carlsbad, CA). Recombinant stem cell factor (SCF) was from PeproTech Inc. (Rocky Hill, NJ).
TissueScan cDNA arrays and quantitative PCR
Quantitative PCR cDNA arrays were conducted using cDNA arrays (Origene, Cancer Survey 
Immunohistochemistry
Slides with sections of formalin-fixed paraffin-embedded (FFPE) normal mammary tissues and patient-derived tumor tissues (Origene and study patients) were incubated in 10 mM citratetween buffer at 97°C for 20 mins for antigen unmasking. Specimens were blocked in 2% goat serum/5% BSA in PBS-tween for 2 hrs, and incubated overnight at 4°C in rabbit anti-MKK3 (C-19, Santa Cruz) at 1:100 in 5% BSA PBS-tween. Slides were then washed and incubated with Alexa 594-conjugated goat anti-rabbit (Invitrogen) at 1:2000 in blocking buffer. Specimens were mounted in DAPI (Vectasheild) and imaged using equivalent settings on a Nikon E600 microscope equipped with 20X or 40X objective lens using ACT-1 software (Nikon).
Quantitative PCR assessment of genomic MKK3 in clinical tumor samples
Human genomic DNA was isolated from random breast cancer patient tumor samples at SinoGenoMax Co. (Beijing, China). Normal female genomic DNA samples were from a random control panel (Sigma, HRC1). Ct values for two distinct genomic sites in the MKK3 gene and Stable colonies of cells were plated under selection by limiting dilution to isolate stable clones.
Plates were incubated for 3 weeks allowing colonies to form. 
Flow cytometry
Cells (5 ×10 5 ) were collected using trypsin (Invitrogen), fixed, and permeabilized using Cytofix/Cytoperm buffer (BD Biosciences) for 20 min. Cells were stained in 100 μl with FITCconjugated Flag antibody (1:1000 or 1 μg/ml) for 2 hr, washed, and analyzed on a FACS Aria (BD Biosciences).
Tumor growth in vivo
For xenotransplantation studies, 1 x10 7 log-phase growing untransfected, MKK3dn, or MKK3ca MDA-MB-468 cells were trypsinized, washed twice in PBS, and injected into immunocomprimised Rag1-deficient mice at the mammary fat pad (200 μl/injection in PBS). At endpoint, tumors were surgically excised, collected, and imaged using an iPhone 4S (Apple).
Tissue specimens were fixed in 10% buffered formalin, embedded in paraffin, sectioned, and stained with haematoxylin and eosin (H&E). 
Cell cycle analysis
Cell cycle staging was conducted using Vybrant DyeCycle Green (Invitrogen) by flow cytometry according to the manufacturer's instructions. Data was analyzed using WinList 5.0 software.
Nuclear protein preparation and electrophoretic mobility shift assay (EMSA)
Nuclear protein extracts were isolated using a nuclear extract kit (Active Motif, Carlsbad, CA) according to the manufacturer's protocol. EMSA was performed as previously described (14) . Double-stranded oligonucleotides for AP-1 and SP-1 consensus binding sequences were from Promega.
Statistical Analysis
The paired Student's t test was used for statistical evaluation of data. Results were considered significant when p < 0.05. Data are expressed as means ± SEM unless otherwise indicated. Genomic copy number variation has emerged as a pervasive phenomenon and an important consideration in a broad range of disease causality including breast cancer (15, 16) , resulting in gene copy number imbalances or loss of heterozygosity (LOH) that can ultimately lead to altered gene expression and protein function (8) . To investigate the copy number status of MKK3 in clinical samples from breast cancer patients, we designed a qPCR assay to assess relative genomic MKK3 content in patient-derived samples. DNA from the NCI-H774 cell line was used to evaluate specificity and create an internal assay control as NCI-H774 cells have a natural double deletion of the MKK3 gene (13) . Remarkably, our analysis revealed a significantly decreased genomic MKK3 level in eight of ten breast cancer patients (Fig. 1C ).
Additional patient tumor data from clinical evaluation of common relevant breast cancer markers is provided (Supplementary Table S1 Fig. S1 ). Further evaluation of tissues from these patients by fluorescence in situ hybridization (FISH) confirmed that MKK3 copy number was heterogeneously reduced, reflecting intra-tumoral genomic heterogeneity at the MKK3 locus (Fig. 1D) . These results are the first to identify a specific MKK3 copy number deficiency and strongly suggest that copy number loss may contribute to reduced MKK3 expression in breast cancer. These findings prompted us to pursue the functional role of MKK3 activity in breast cancer. (Fig. 2B) . Following the trend in tumor growth, a remarkable MKK3 activity-dependent difference in the density of intratumoral MDA-MB-468 cells was observable by histological staining (Fig. 2C) . These results indicate that MKK3 activity is suppressive of breast cancer tumor growth, and conversely, that impaired MKK3 signals lead to significantly enhanced breast cancer tumor growth.
To directly determine the role of MKK3 activity on tumor cell proliferation, in vitro studies were conducted using five independently derived MKK3dn and MKK3ca cell lines.
MKK3 activity had a significant impact on basal proliferation, with MKK3ca cells at 64% and MKK3dn cells at 229% of the proliferative rate of untransfected cells (Fig. 3A) . These results were further confirmed using a WST-1 proliferation assay (Fig. 3B) and by counting equivalently seeded cells in culture (Fig. 3C-D) . In accordance with our observations on in vivo tumor growth, these findings indicate that MKK3 activity inhibits tumor cell proliferation, and conversely, that a lack of MKK3 signalling may enhance breast cancer tumor growth via enhanced tumor cell proliferation. 
significantly oppositely regulated was cyclin-dependent kinase inhibitor 1A (CDKN1A), the gene encoding the inhibitor of cell cycle progression p21 Cip1/Waf1 (Fig. 4A) . Quantitative analysis showed that CDKN1A expression in MKK3ca was 2.56-fold while that of MKK3dn cells was 0.66-fold compared to control cells (Fig. 4A) . The full array data set is presented in Supplementary Table S2 .
To confirm our gene expression analysis at the protein level, Western blots were conducted to analyze the expression of a panel of cyclin-dependent kinase (CDK) inhibitors.
Indeed, opposing expression of p21 protein was detected in MKK3-mutant cell lines in accordance with mRNA levels detected by qPCR (Fig. 4B) . Notably, another CDK inhibitor, p27 Kip1 (CDKN1B), was similarly oppositely deregulated in mutant MKK3 cell lines (Fig. 4B) .
Expression of family member p16 (CDKN2A) was in accordance with qPCR data and, as in the case of p15 (CDKN2B), was not significantly oppositely regulated by MKK3 (Fig. 4B) , while remaining members p18 and p57 were not detectable (data not shown). Phosphorylation of p21 in a p38-dependent mechanism has been reported to stabilize p21 protein (18) . We analyzed p21
at Ser130 in our cell lines and could not detect any phosphorylation at this site, suggesting that this mechanism is not playing a role in our system. 
stimulated for activation of the MAPK pathway through the stem cell factor receptor c-kit (Fig.   5A ). The tumor suppressor p53 is a major regulator of p21 and p27 gene expression, however p53-dependent and p53-independent mechanisms are known (20) (21) (22) . Notably however, MDA-MB-468 cells express a mutant p53 protein with the R273H mutation which results in defective DNA contact and binding, suggesting that the MKK3 activity-dependent effect is unlikely to be mediated by p53 (23), but to confirm this was case, we conducted further analysis of p53 activation. To determine if MKK3 signaling activity modifies p53 phosphorylation and activation in MKK3ca cells, Western blotting for activation of the p53 protein was conducted.
No MKK3-dependent activation of p53 consistent with activation of p21 and p27 was detectable.
In fact, MKK3 signals led to dephosphorylation of p53 at Ser9, and in general, inconsistent with a p53-dependent mechanism, total p53 protein expression was slightly enhanced in MKK3dn cells (Fig. 5B) . In addition to those shown in Figure 5B , phosphorylation analysis was also conducted at Ser6 and Thr81, but no phosphorylation was detected at these sites. These results suggest that MKK3-activity regulates p21 and p27 expression independently of p53 phosphorylation.
We then further examined the role of p53 in our MKK3 transfected cell lines by siRNAmediated knockdown of p53. Knockdown of p53 resulted in enhanced expression of both p21 and p27 in all cell lines, and did not impair the enhanced p21 and p27 expression in MKK3ca cells (Fig. 5C ). Overall enhanced expression in the knockdowns is likely an effect of removal of the dominant negative and/or gain-of-function effects exerted by the mutant protein on basal p53 target gene expression. These results suggest that in our cell lines, mutant p53 is inhibitory to basal expression of p21 and p27, and that MKK3 can direct p21 and p27 expression in the absence of functional p53. Finally, we examined our cell lines by chromatin weak interactions between p53 and the p21 promoter, which is not surprising given a functionally defective p53. Altogether, these results suggest that MKK3 activity driven expression of p21 and p27 is occurring via p53-independent mechanism in our model.
The AP-1 transcription factor can also control p21 gene expression through activation of SP-1 promoter binding (24) . Gene expression array data indicated that c-Jun, a component of AP-1, was oppositely regulated in MKK3-mutant cells, consistent with p21 (Fig. 4A) . MKK3-dependent protein expression of c-Jun was confirmed by Western blotting (Fig. 6B) . However, investigation of the DNA-binding activity of AP-1 and SP-1 revealed that their activities were not notably altered in the MKK3-mutant cells (Fig. 6C) , suggesting that this mechanism is unlikely to be contributing to MKK3-directed p21 expression.
MKK3 activity promotes p21/p27-mediated G 1 cell cycle arrest, inhibiting tumor growth.
Cell cycle regulators p21 and p27 inhibit cell cycle progression at the G 1 checkpoint (25), a considerably attractive mechanism to target in cancer (26) (27) (28) (29) (30) . Recent studies in glioblastoma proliferation have shown that a natural plant product, β-elemene, inhibits tumor growth by arresting cells in the G 0 /G 1 phase through a mechanism dependent on MKK3 activation (31) . To MKK3ca cells showed significant cell cycle arrest at the G 1 phase, while MKK3dn cells had significantly reduced numbers in G 1 indicating a more rapid entry into the S phase. Accordingly, MKK3ca cells had significantly fewer numbers in the G 2 /M mitotic phase, while MKK3dn cells had enhanced numbers in S and G 2 /M (Fig. 7A) . Collectively, these results identify MKK3 as a novel tumor suppressor in breast cancer that is downregulated in a range of cancer types, and suggest that active MKK3 promotes G 1 cell cycle arrest and restricts tumor cell proliferation by enhancing p21 and p27 expression, resulting in suppressed tumor growth, while impaired MKK3 signals have the opposing effect on both gene expression and tumor growth (Fig. 7B) .
Discussion
Addressing the significance of MKK3 in breast and other types of cancer has garnered increasing interest in recent years as efforts continue to decipher the elusive role of the MAPK pathway in carcinogenesis and tumor suppression (3) . In this study, we have identified a new tumor suppressive role for the mitogenic signalling protein MKK3 in the regulation of breast cancer tumor growth. We have characterized this function mechanistically to be mediated by MKK3 signalling activity-dependent regulation of the expression of cell cycle inhibitors, p21 and p27, and subsequent restriction of cell cycle progression, as shown in our proposed model (Fig. 7B) . Importantly, we demonstrate that MKK3 expression is significantly impaired in breast cancer tissues, and describe a novel loss of MKK3 genomic copy number in breast cancer patients. This is the first specific detection of MKK3 copy number variation in human cancer and suggests that MKK3 is a suppressor of mammary carcinogenesis with potential prognostic, predictive, and/or therapeutic value. In breast cancer, inactivation of the MAPK phosphatase Wip1 inhibits mammary carcinogenesis. Wip1 functions to inactivate signals mediated by MKK3 through the p38 MAPK pathway, supporting a suppressive role for MKK3 signalling in breast cancer pathogenesis (32, 33) . Our mechanistic results expand significantly on how MKK3 activity inhibits carcinogenesis, through promotion of cell cycle arrest. Inhibition of cell cycle progression is clearly an attractive mechanism to target and promote in the development of anti-cancer therapies, and the significance of p21 and p27 expression in this mechanism has not been understated in the literature (26) (27) (28) 34) . In breast cancer, p21 and p27 have received considerable attention as clinical indicators and potential targets in therapeutic development (28) (29) (30) . In agreement with the findings we present here, previous work in leukemia showed that impaired MKK3 signals enhanced prostaglandin PGJ2-induced proliferation, and described impaired p21 and p27 expression in treated THP-1 cells (35) . Additionally, a natural fungal product (FTY720) induced MKK3 activity and p21 expression in prostate cancer cells, leading to cell cycle arrest (36) , while studies in muscle cell differentiation have shown that dominant negative MKK3 inhibits p21 and p27 expression (37) . Downstream of MKK3, p38 MAPK activity is linked to p27 expression, leading to contact inhibition in mouse embryonic stem cells (38, 39) , and it is also well-known that p38 can activate p53-dependent p21 expression (40) , and further stabilize p21 protein by direct phosphorylation (18) . While these reports suggest MKK3 signals are linked to p21 and p27 expression, we report the first direct evidence that active MKK3 is a vital regulator of these two cycle cell inhibitors, independent of p53 activation, with ramifications in tumor progression, and may represent a novel approach to targeting cell cycle inhibition in cancer.
Induction of p21 transcription and resultant cell cycle arrest is associated with both p53-dependent and p53-indpednent mechanisms (20, 22, 34 
activate p21 expression in a p53-dependent manner inducing transient senescence preceding DNA repair or apoptosis (41), whereas p53-independent p21 induction is more associated with the induction of cellular senescence, differentiation, and development (20) . The p38 MAPK, a direct substrate of MKK3, can itself activate p53 at Ser15, Ser33, and Ser46, leading to p21 transcription (3, 42, 43) . To determine if MKK3 activity-dependent p21 expression was regulated by p53, we examined p53 phosphorylation at a range of sites, including Ser46, Ser15, and Ser392, which are known to lead to p53-dependent p21 transcription (44) (45) (46) , and found no altered p53 activation. Notably, total p53 protein was actually slightly enhanced in MKK3dn cells. We also examined the contribution of p53 by knockdown and by ChIP analysis of promoter-association. Altogether, these results support a p53-indpendent transcriptional regulation of p21 by MKK3 activity. Interestingly, our results may have additional relevance in cases of p53 mutation, which occur in up to 50% of cancers, given that our results describe a scenario of p53 mutation in which p21 and p27 expression is actively repressed by the R273H mutant p53.
Interestingly, p21 and p27 expression are known to be upregulated by inhibition of the PI3K/Akt signalling pathway leading to G 1 cell cycle arrest (47) , and indeed MKK3ca MDA-MB-468 cells had impaired activation of this pathway when Akt phosphorylation was examined ( Supplementary Fig. S3 ), suggesting that MKK3 signals can inhibit Akt activation thereby supporting p21 and p27 expression. Aside from a transcription factor activation-mediated mechanism acting directly on the p21 and p27 promoters, an alternative mode of action could be through mRNA stability. MKK3 signalling is associated with increased mRNA stability of transcripts with adenosine/uridine-rich elements in the 3'UTR in breast cancer cells (48) , and p21 and p27 expression are known to be regulated through RNA stabilization mechanisms (49) (50) (51) 
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remains unclear precisely how MKK3 activity can direct p21 and p27 expression leading to cell cycle arrest.
Despite extensive interest in a tumor suppressive role for MAPK signalling, this study is, to our knowledge, the first direct assessment of MKK3 activity on tumor growth in an in vivo xenograft model. We report a novel p53-independent mechanistic regulation of cell cycle inhibitors p21 and p27, dependent on MKK3 activity, leading to cell cycle arrest at G 1 and significantly impaired tumor growth in vivo. Moreover, we identify a prevalent loss of MKK3 genomic copy number in breast cancer patients, and significantly impaired gene and protein expression in malignant mammary tissues. Collectively, these results position MKK3 as a novel tumor suppressor that is altered in human breast cancer. 
